LXRX241220P1000
- 0.30
- +0.10+50.00%
Lexicon Pharmaceuticals Newsroom
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Cuts Target Price to $1.2
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
Lexicon Pharmaceuticals: Strategic Focus on Promising Pipeline Amid Clinical Progress and Restructuring
Express News | Lexicon Pharmaceuticals Inc - Top-Line Data From Progress Study Expected in Q1 2025
Express News | Lexicon Announces Completion of Enrollment in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Express News | Lexicon Pharmaceuticals Inc : Jefferies Cuts Target Price to $0.8 From $1.4
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Sector Update: Health Care
Needham Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating
Needham Reiterates Hold on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Analyst Ratings
HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating
Lexicon Pharmaceuticals to Cut 60% of Workforce
Lexicon Falls on Restructuring Program
Lexicon Pharmaceuticals Says Company Has Made Strategic Decision To Eliminate Its Commercial Operations And Rationalize Resources Across All Functions In Order To Preserve Cash And Focus Its Resources On Advancing Promising Clinical Development...
Express News | Lexicon Pharmaceuticals Inc: Receipt of a "Deficiencies Preclude Discussion" Letter From FDA Regarding Nda for Zynquista
Express News | Lexicon Pharmaceuticals Inc: Elimination of Promotional Efforts for Inpefa, Planned Commercial Activities for Zynquista